Tavalisse (Fostamatinib Disodium) Patent Expiration, LOE Window & CMS Spending
Tavalisse (Fostamatinib Disodium) by Rigel Pharmaceuticals: FDA Orange Book core substance LOE 2031-09-04 (last listed 2032-07-27), 1 AB generics, $62.3M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Rigel Pharmaceuticals |
| FDA Application & Pathway | N209299 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2031-09-04 |
| Last Listed Patent or Exclusivity Date | 2032-07-27 |
| Orange Book Patents (*PED Extensions) | 14 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $62.3M |
| 2024 Medicare Part D Spend | $47.4M |
| 2024 Medicaid Spend | $14.9M |
| Reported Wholesale Price Change (CA SB 17) | 6 WAC filings (max 17.9% 2-yr change) |